Faeth Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Sensei Biotherapeutics, Inc. | |||
| Date: | March 28, 2025 | By: | /s/ John Celebi |
|---|---|---|---|
| John Celebi | |||
| President and Chief Executive Officer | |||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ John Celebi | President, Chief Executive Officer and Director (Principal Executive Officer) | March 28, 2025 |
| John Celebi | ||
| /s/ Josiah Craver | Senior Vice President of Finance (Principal Financial and Accounting Officer) | March 28, 2025 |
| Josiah Craver | ||
| /s/ William Ringo | Chair | March 28, 2025 |
| William Ringo | ||
| /s/ Bob Holmen | Director | March 28, 2025 |
| Bob Holmen | ||
| /s/ James Peyer, Ph.D. | Director | March 28, 2025 |
| James Peyer, Ph.D. | ||
| /s/ Thomas Ricks | Director | March 28, 2025 |
| Thomas Ricks | ||
| /s/ Kristian Humer | Director | March 28, 2025 |
| Kristian Humer | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Common Stock and Stockholders’ Equity for the Years Ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.